LD-2 disclosure · 4th Quarter - Report
LUNDBECK PHARMACEUTICALS LLC
Client
- Description
- Specialty and Central Nervous System Bio-pharmaceutical manufacturing.
- Location
- Illinois · United States of America
Registrant
- Description
- Government affairs.
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
2 issuesHealth Issues
Issues regarding Pill Penalty caused by the Inflation Reduction Act (IRA) P.L. No: 117-169, drug pricing, and efforts to create a Neuroscience Center of Excellence at FDA. PBM Issues, including H.R./S._Modernizing and Ensuring PBM Accountability Act.
LobbyistsSHANNON FINLEY · LUKE HATZIS · ANN JABLON · JOSEPH EANNELLO · JEFFREY CARROLL · JOHN MARTIN · KAREN STONE · mr CHARLES PATRICK MICHAELS
Covered position (KAREN STONE): Office of former Congressman Steve Israel (D-NY) [Legislative Correspondent/Staff Assistant, 2005; Senior Legislative Assistant, 2005-2009] Office of Congresswoman Dina Titus (D-NV) [Legislative Director, 2009-2010].
TargetedSENATE · HOUSE OF REPRESENTATIVES
Medicare/Medicaid
Issues regarding the Inflation Reduction Act (IRA) P.L. No: 117-169, drug pricing, and efforts to create a Neuroscience Center of Excellence at FDA. PBM Issues, including H.R./S._ Modernizing and Ensuring PBM Accountability Act and H.R./S._Lower Costs, More Transparency Act. Issues regarding effective solutions for improving clinical care in long-term care settings and other solutions aimed at improving the diagnosis and management of neuropsychiatric symptoms (NPS) in dementia. Orphan Drug Provisions included in HR.1, the One Big Beautiful Bill Act (OBBB) P.L. 119-21.
LobbyistsSHANNON FINLEY · LUKE HATZIS · ANN JABLON · JOSEPH EANNELLO · JEFFREY CARROLL · JOHN MARTIN · KAREN STONE · mr CHARLES PATRICK MICHAELS
TargetedSENATE · HOUSE OF REPRESENTATIVES